文献速递冠心病血脂与心血管预防

高强度降脂治疗下冠状动脉粥样斑块三联逆转与稳定

Concomitant Coronary Atheroma Regression and Stabilization in Response to Lipid-Lowering Therapy.
PubMed 文献 · J Am Coll Cardiol · 2023-08-26

PACMAN-AMI 试验对急性心肌梗死患者行系列血管内超声、近红外光谱和光学相干断层扫描,比较高强度他汀基础上阿利西尤单抗与安慰剂的效应。31.7% 患者出现斑块体积百分比降低、最大脂质核心负荷指数降低和最小纤维帽厚度增加的三联逆转,阿利西尤单抗组发生率更高且临床事件更少。

要点

  • 三联逆转见于 31.7% 急性心梗并接受高强度降脂治疗的患者。
  • 阿利西尤单抗组三联逆转率 40.8%,高于安慰剂组 23.0%。
  • 三联逆转者 1 年死亡、心梗和缺血驱动血运重建复合终点更少。

核心结论

  • 三联逆转见于约三分之一接受高强度降脂治疗的急性心梗患者,与阿利西尤单抗治疗、较高基线脂质含量及较少心血管事件相关。

研究设计与样本

  • PACMAN-AMI 试验用系列血管内超声、近红外光谱和光学相干断层扫描比较阿利西尤单抗与安慰剂。
  • 患者均接受高强度他汀治疗,评估 1 年随访临床结局。

主要发现

  • 84 例(31.7%)出现三联逆转,阿利西尤单抗组 40.8% 对安慰剂组 23.0%(P = 0.002)。
  • 三联逆转者治疗中低密度脂蛋白胆固醇更低,组间差 -27.1 mg/dL(95%CI:-37.7 至 -16.6 mg/dL;P < 0.001)。
  • 阿利西尤单抗治疗独立预测三联逆转(OR:2.83;95%CI:1.57-5.16;P = 0.001)。
  • 较高基线最大脂质核心负荷指数独立预测三联逆转(OR:1.03;95%CI:1.01-1.06;P = 0.013)。
  • 死亡、心肌梗死和缺血驱动血运重建复合终点在三联逆转者中更少(8.3% 对 18.2%;P = 0.04)。

关键数值与推荐

  • 三联逆转定义为斑块体积百分比降低、4 mm 内最大脂质核心负荷指数降低和最小纤维帽厚度增加同时存在。

临床怎么用

  • 急性心梗后高强度降脂治疗中可评估斑块三联逆转,阿利西尤单抗治疗与更高逆转率相关。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The frequency, characteristics, and outcomes of patients treated with high-intensity lipid-lowering therapy and showing concomitant atheroma volume reduction, lipid content reduction, and increase in fibrous cap thickness (ie, triple regression) are unknown. OBJECTIVES: This study was designed to investigate rates, determinants, and prognostic implications of triple regression in patients presenting with acute myocardial infarction and treated with high-intensity lipid-lowering therapy. METHODS: The PACMAN-AMI (Effects of the PCSK9 Antibody Alirocumab on Coronary Atherosclerosis in Patients with Acute Myocardial Infarction) trial used serial intravascular ultrasound, near-infrared spectroscopy, and optical coherence tomography to compare the effects of alirocumab vs placebo in patients receiving high-intensity statin therapy. Triple regression was defined by the combined presence of percentage of atheroma volume reduction, maximum lipid core burden index within 4 mm reduction, and minimal fibrous cap thickness increase. Clinical outcomes at 1-year follow-up were assessed. RESULTS: Overall, 84 patients (31.7%) showed triple regression (40.8% in the alirocumab group vs 23.0% in the placebo group; P = 0.002). On-treatment low-density lipoprotein cholesterol levels were lower in patients with vs without triple regression (between-group difference: -27.1 mg/dL; 95% CI: -37.7 to -16.6 mg/dL; P < 0.001). Triple regression was independently predicted by alirocumab treatment (OR: 2.83; 95% CI: 1.57-5.16; P = 0.001) and a higher baseline maximum lipid core burden index within 4 mm (OR: 1.03; 95% CI: 1.01-1.06; P = 0.013). The composite clinical endpoint of death, myocardial infarction, and ischemia-driven revascularization occurred less frequently in patients with vs without triple regression (8.3% vs 18.2%; P = 0.04). CONCLUSIONS: Triple regression occurred in one-third of patients with acute myocardial infarction who were receiving high-intensity lipid-lowering therapy and was associated with alirocumab treatment, higher baseline lipid content, and reduced cardiovascular events. (Vascular Effects of Alirocumab in Acute MI-Patients [PACMAN-AMI]; NCT03067844).

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Biccirè FG, Häner J, Losdat S, et al. Concomitant Coronary Atheroma Regression and Stabilization in Response to Lipid-Lowering Therapy. J Am Coll Cardiol. 2023. PMID: 37640248. doi:10.1016/j.jacc.2023.08.019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。